Beyond Reporting - Safety surveillance analytics for medical devices...
Complex Journey from Innovation to Patient impact
Two Acts, One Geopolitical Moment
LYMPHOMA TREATMENT AT A CROSSROADS
Long-acting Injectable Formulations
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Bioquell Asia Pacific,
Managing Director
Bioquell Asia Pacific based in Singapore in April to be the regional office for our activities in Asia and Australasia I am responsible for the development of our business throughout the region and for the success and profitability of our activities We provide equipment and services for environmental biodecontamination across the pharmaceutical therapeutic development
Articles
The Use of AI in Pharmacovigilance
Regulatory authorities RAs across the world are showing increased interest in the use and applications of artificial intelligence AI in pharmacovigilance PV At the same time these new cognitive technologies have generated concerns in the regulatory space public health and the life sciences industry RAs from different regions are focusing their efforts on developing standards and good practices for...
Research Insights
How Fast are Viruses Spreading in the Wild?
Genomic data collected from viral outbreaks can be exploited to reconstruct the dispersal history of viral lineages in a twodimensional space using continuous phylogeographic inference These spatially explicit reconstructions can subsequently be used to estimate dispersal metrics that can be informative of the dispersal dynamics and the capacity to spread among hosts
Case Studies
<sup>14</sup>C microtracer+Accelerator Mass Spectrometry - Xceleron Case Studies
Introduction Xceleron is a world leader in the use of Accelerator Mass Spectrometry AMS analytical technology in pharmaceutical food technology crop protection and biobased product applications Our primary business is in pharmaceutical research and development Since we have been helping to design preclinical and clinical investigations around the
Techno Trends
Nanopore-based DNA Sequencing Technology to Diagnose Genetic Disorder Huntington's Disease
Nanoporebased DNA sequencing technology has been developed to diagnose the genetic disorder Huntingtons Diseases for the first time in the world
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.
Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.
Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.
Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.
Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.
Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.
Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.
Application of Artificial Intelligence in Development Safety Update Report Preparation
Maria Carolina Braga holds a degree in Pharmaceutical Sciences with a specialization in Clinical Pharmacy. She has over 10 years of experience in pharmacovigilance and recently completed a master’s degree in Pharmacovigilance and Pharmacoepidemiology, focusing her research on the use of artificial intelligence in aggregate safety report writing.
Mussel-inspired Bio-adhesives
Amisha Raikar is a highly motivated individual with a strong educational background in the field of pharmaceutics. She completed her Bachelor of Pharmacy (B-Pharm) from Goa University in 2022, which laid the foundation for her journey into the pharmaceutical industry. Building upon her undergraduate degree, Amisha decided to pursue Master of Pharmacy (M-Pharm) in pharmaceutical science and formulation development. Recognising the importance of expanding her skill set beyond the technical aspects of pharmaceuticals, she embarked on a Postgraduate Diploma in International Business Management from the Indira Gandhi National Open University (IGNOU). Amisha's passion for learning and her desire to contribute to the field of pharmaceuticals has fueled her interest in pursuing a Ph.D. With her strong educational background, practical experience, and an eagerness to pursue further studies, Amisha Raikar is poised to make significant contributions to the field of pharmaceuticals through her future endeavours, such as a Ph.D. program.
Quercetin - A Super Food For Therapeutic Interventions
Mohini Sikarwar is a PhD Scholar at Centre for Development of Biomaterials, Sharda University, Greater Noida, India. Her research is focusing on advanced drug delivery systems with a commitment to enhancing therapeutic efficacy of poorly water-soluble drug for Leishmaniasis treatment. She is aiming to revolutionise the current treatment methods of Kala azar using drug delivery approaches.
Dr. Piyush Kumar Gupta is currently head of the Centre for Development of Biomaterials at Sharda University, Greater Noida, India. His area of expertise belongs to Biomaterials, Pharmaceutics, and Nanotoxicology. He has published 143 SCIE and Scopus-indexed peer-reviewed articles and 7 book chapters in his area of expertise. He has been bestowed with several International or National awards.
Decoding Antisense Oligonucleotides: Mechanisms, Applications, and Future Directions
Dr. Arun Shastry is a Bengaluru-based scientist with a PhD in Immunogenetics. He is the Co-Founder, Managing Director, and Chief Scientific Officer (CSO) of Hanugen Therapeutics, a pioneering biopharmaceutical company focused on oligonucleotide-based therapies for rare genetic diseases, particularly Duchenne Muscular Dystrophy (DMD). With over two decades in drug discovery for rare disorders, Dr. Shastry drives affordable, accessible treatments through innovative personalized medicine approaches in India.
press releasesRead more...
Roche opens up new possibilities for genomic research in Asia Pacific with next-generation sequencing technology
Roche is advancing its nextgeneration sequencing NGS ambitions in Asia Pacific following the global launch of AXELIOS in June Building on early adoption in South Korea Roche will bring the transformative technology closer to researchers and laboratory leaders across the region through AXELIOS Days
Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses
Charles River Laboratories International Inc announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporations bioanalysis and DMPK operations in Exton Pennsylvania for approximately million in cash subject to customary closing adjustments In addition to the i...
Sino Biological Advances AI-Designed Molecule Validation with 4RISETM
AI can generate protein candidates at an unprecedented speed but experimental validation remains essential to determine whether they properly express bind targets and demonstrate the desired biological properties Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in recombinant protein t...
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
LATEST NEWSRead more...
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention
Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
